Cassava sciences announces science publication that confirms mechanism of action of simufilam, a novel drug candidate for people with alzheimer's disease

Austin, texas, sept. 13, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a biotechnology company focused on alzheimer's disease, today announced the publication of new research that confirms the biological activity of simufilam. simufilam is cassava sciences' novel drug candidate for people with alzheimer's disease dementia and is currently under evaluation in a pair of global phase 3 clinical trials.
SAVA Ratings Summary
SAVA Quant Ranking